Cargando…

Ovarian function suppression as a potential mechanism of chemotherapy

Detalles Bibliográficos
Autores principales:	Gomez Marti, Juan Luis, Nasrazadani, Azadeh, Brufsky, Adam M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318981/ https://www.ncbi.nlm.nih.gov/pubmed/34280778 http://dx.doi.org/10.1016/j.ebiom.2021.103489

Ejemplares similares

Artificial intelligence-directed prognostication of breast cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2019)

Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection
por: Brufsky, Adam, et al.
Publicado: (2020)

Statins and endocrine resistance in breast cancer
por: Hyder, Tara, et al.
Publicado: (2021)

Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
por: Gomez Marti, Juan Luis, et al.
Publicado: (2023)

Breast cancer mortality as a function of age
por: Nasrazadani, Azadeh, et al.
Publicado: (2022)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021)

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
por: Hyder, Tara, et al.
Publicado: (2021)

Distinct viral clades of SARS‐CoV‐2: Implications for modeling of viral spread
por: Brufsky, Adam
Publicado: (2020)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

DC/L‐SIGNs of hope in the COVID‐19 pandemic
por: Brufsky, Adam, et al.
Publicado: (2020)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer
por: Gomez Marti, Juan Luis, et al.
Publicado: (2022)

Combination chemotherapy regimen in a patient with metastatic malignant pheochromocytoma and neurofibromatosis type 1
por: Otoukesh, Salman, et al.
Publicado: (2014)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Brufsky, Adam M.
Publicado: (2015)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

Can supervised group‐based multimodal exercise improve health‐related quality of life in women with ovarian cancer undergoing chemotherapy?
por: Dybeck, Mette‐Marie, et al.
Publicado: (2022)

In vivo sites and cellular mechanisms of T reg cell–mediated suppression
por: Rudensky, Alexander Y., et al.
Publicado: (2006)

Potential Biases in Studies of Acid-Suppressing Drugs and COVID-19 Infection
por: Etminan, Mahyar, et al.
Publicado: (2021)

A Potential Chinese Medicine Granule Suppressing ARDS of COVID-19: Keguan-1
por: Zhong, Nan-shan, et al.
Publicado: (2020)

Patient preferences for chemotherapies used in breast cancer
por: Beusterien, Kathleen, et al.
Publicado: (2012)

The Clinical Potential of IL-12/IL-35 in Treating Chemotherapy Drug-induced Cardiac Injury
por: Jia, Zhanjun
Publicado: (2018)

Precision Medicine in Hormone Receptor-Positive Breast Cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2018)

Possible mechanism and clinical potentials of allostery
por: Huang, Peixin, et al.
Publicado: (2014)

Mechanisms of chemotherapy resistance in ovarian cancer
por: Ortiz, Mylena, et al.
Publicado: (2022)

Thoracic fluid accumulation and asthma symptoms: A new contributor mechanism
por: Francisco, Cristina de Oliveira, et al.
Publicado: (2019)

The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury – Authors' reply
por: Ye, Jing, et al.
Publicado: (2018)

Loss of tumor suppressive properties of lipid metabolism enzyme CPT2 in ovarian carcinoma: Comment on “CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer” by Zhang et al.
por: Vlachostergios, Panagiotis J.
Publicado: (2021)

Species-specific mechanisms of tumor suppression are fundamental drivers of vertebrate speciation: critical implications for the ‘war on cancer’
por: Nyce, Jonathan W
Publicado: (2018)

Palliative chemotherapy: oxymoron or misunderstanding?
por: Roeland, EJ, et al.
Publicado: (2016)

Neoadjuvant Chemotherapy for Colon Cancer
por: Roth, Marc T., et al.
Publicado: (2020)

Hepatic metastases in ovarian cancer
por: Shan, Ying, et al.
Publicado: (2022)

Understanding decreased fertility in women carriers of the FMR1 premutation: a possible mechanism for Fragile X-Associated Primary Ovarian Insufficiency (FXPOI)
por: Peprah, Emmanuel
Publicado: (2014)

Circadian clock genes, ovarian development and diapause
por: Bradshaw, William E, et al.
Publicado: (2010)

Hyperglycemia and acquired weakness in critically ill patients: potential mechanisms
por: Callahan, Leigh Ann, et al.
Publicado: (2009)

Multi-kinase inhibition in ovarian cancer
por: Dent, Paul
Publicado: (2014)

Acetyltransferases and tumour suppression
por: Phillips, A C, et al.
Publicado: (2000)

Fractalkine signaling in regulation of insulin secretion: Mechanisms and potential therapeutic implications?
por: Gregg, Brigid, et al.
Publicado: (2014)

Uncovering Potential Mechanisms of the Relationship Between Structural Deficits and General Psychopathology
por: Kaczkurkin, Antonia N.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bihli0bb5513ikccoks8h4c9kt